{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T13:08:37Z","timestamp":1793452117792,"version":"4.5.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T00:00:00Z","timestamp":1756425600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T00:00:00Z","timestamp":1756425600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s40265-025-02207-8","type":"journal-article","created":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T11:03:59Z","timestamp":1756465439000},"page":"1329-1333","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Linvoseltamab: First Approval"],"prefix":"10.1007","volume":"85","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6519-7831","authenticated-orcid":false,"given":"Arnold","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,29]]},"reference":[{"issue":"5","key":"2207_CR1","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.clml.2024.11.012","volume":"25","author":"JM Waldschmidt","year":"2025","unstructured":"Waldschmidt JM, Rasche L, Kort\u00fcm KM, et al. Comprehensive review of bispecific antibody constructs in multiple myeloma: affinities, dosing strategies and future perspectives. Clin Lymphoma Myeloma Leuk. 2025;25(5):309\u201315.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2207_CR2","unstructured":"Regeneron Pharmaceuticals, Inc. Regeneron clinical pipeline. 2025. https:\/\/www.regeneron.com\/. Accessed 20 May 2025."},{"key":"2207_CR3","unstructured":"Regeneron Pharmaceuticals, Inc. Lynozyfic\u2122 (linvoseltamab) approved in the European Union for the treatment of relapsed\/refractory multiple myeloma [media release]. 28 Apr 2025. https:\/\/investor.regeneron.com\/."},{"key":"2207_CR4","unstructured":"Regeneron Pharmaceuticals, Inc. Lynozyfic\u2122 (linvoseltamab-gcpt) receives FDA accelerated approval for treatment of relapsed or refractory multiple myeloma [media release]. 2 Jul 2025. https:\/\/investor.regeneron.com\/."},{"key":"2207_CR5","unstructured":"Regeneron Ireland DAC. LYNOZYFIC (linvoseltamab): summary of product characteristics. 2025. https:\/\/www.ema.europa.eu\/. Accessed 1 May 2025."},{"key":"2207_CR6","unstructured":"Janssen Biotech, Inc. TECVAYLI (teclistamab-cqyv) injection: US prescribing information. 2024. https:\/\/www.fda.gov. Accessed 17 June 2025."},{"key":"2207_CR7","unstructured":"Pfizer, Inc. ELREXFIO (elranatamab-bcmm) injection: US prescribing information. 2023. https:\/\/www.fda.gov. Accessed 17 June 2025."},{"key":"2207_CR8","unstructured":"Regeneron Pharmaceuticals, Inc. Regeneron and Sanofi launch major new immuno-oncology collaboration [media release]. 28 Jul 2015. https:\/\/investor.regeneron.com\/."},{"key":"2207_CR9","unstructured":"Regeneron Pharmaceuticals, Inc, Sanofi. Regeneron and Sanofi restructure immuno-oncology collaboration for discovery and development programs [media release]. 7 Jan 2019. https:\/\/investor.regeneron.com\/."},{"key":"2207_CR10","unstructured":"SpringWorks Therapeutics, Inc. SpringWorks Therapeutics announces clinical trial collaboration and supply agreement with Regeneron to evaluate nirogacestat in combination with REGN5458 in patients with relapsed or refractory multiple myeloma [media release]. 19 Apr 2022. http:\/\/www.springworkstx.com."},{"issue":"5","key":"2207_CR11","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1182\/bloodadvances.2020002736","volume":"5","author":"DJ DiLillo","year":"2021","unstructured":"DiLillo DJ, Olson K, Mohrs K, et al. A BCMAxCD3 bispecific T cell-engaging antibody demonstrates robust antitumor efficacy similar to that of anti-BCMA CAR T cells. Blood Adv. 2021;5(5):1291\u2013304.","journal-title":"Blood Adv"},{"issue":"Suppl 1","key":"2207_CR12","doi-asserted-by":"publisher","first-page":"3265","DOI":"10.1182\/blood-2024-208776","volume":"144","author":"K Lee","year":"2024","unstructured":"Lee K, Zhou Y, Franklin M, et al. Characterization of linvoseltamab\u2019s BCMA binding epitope and efficacy against BCMA mutations in relapsed\/refractory multiple myeloma. Blood. 2024;144(Suppl 1):3265.","journal-title":"Blood"},{"issue":"9","key":"2207_CR13","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1038\/s41591-023-02491-5","volume":"29","author":"H Lee","year":"2023","unstructured":"Lee H, Ahn S, Maity R, et al. Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma. Nat Med. 2023;29(9):2295\u2013306.","journal-title":"Nat Med"},{"issue":"22","key":"2207_CR14","doi-asserted-by":"publisher","first-page":"2702","DOI":"10.1200\/JCO.24.01008","volume":"42","author":"N Bumma","year":"2024","unstructured":"Bumma N, Richter J, Jagannath S, et al. Linvoseltamab for treatment of relapsed\/refractory multiple myeloma. J Clin Oncol. 2024;42(22):2702\u201312.","journal-title":"J Clin Oncol"},{"issue":"16 Suppl","key":"2207_CR15","doi-asserted-by":"publisher","first-page":"7561","DOI":"10.1200\/JCO.2024.42.16_suppl.7561","volume":"42","author":"S Kumar","year":"2024","unstructured":"Kumar S, Weisel K, Ma Q, et al. Comparative effectiveness of linvoseltamab versus standard-of-care (SOC) treatment (tx) in real-world patients (pts) in the United States (US) with triple-class exposed (TCE) relapsed\/refractory multiple myeloma (RRMM). J Clin Oncol. 2024;42(16 Suppl):7561.","journal-title":"J Clin Oncol"},{"issue":"16 Suppl","key":"2207_CR16","doi-asserted-by":"publisher","first-page":"7560","DOI":"10.1200\/JCO.2024.42.16_suppl.7560","volume":"42","author":"S Jagannath","year":"2024","unstructured":"Jagannath S, Lee H, Richter J, et al. Indirect comparison of linvoseltamab versus teclistamab for triple-class exposed (TCE) relapsed\/refractory multiple myeloma (RRMM). J Clin Oncol. 2024;42(16 Suppl):7560.","journal-title":"J Clin Oncol"},{"issue":"Suppl 2","key":"2207_CR17","doi-asserted-by":"publisher","first-page":"S267","DOI":"10.1016\/S2152-2650(24)02305-X","volume":"24","author":"J Zonder","year":"2024","unstructured":"Zonder J, Lee H, Richter J, et al. Indirect comparison of linvoseltamab versus selinexor plus dexamethasone for penta-exposed relapsed\/refractory multiple myeloma (RRMM). Clin Lymphoma Myeloma Leuk. 2024;24(Suppl 2):S267.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"Suppl 2","key":"2207_CR18","doi-asserted-by":"publisher","first-page":"S274","DOI":"10.1016\/S2152-2650(24)02317-6","volume":"24","author":"J Richter","year":"2024","unstructured":"Richter J, Jagannath S, Lee H, et al. Indirect comparison of linvoseltamab versus talquetamab for triple-class exposed (TCE) relapsed\/refractory multiple myeloma (RRMM). Clin Lymphoma Myeloma Leuk. 2024;24(Suppl 2):S274\u20135.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2207_CR19","unstructured":"Zonder JA, Richter J, Jagannath S. Linvoseltamab in patients identifying as Black or African American with relapsed\/refractory multiple myeloma (RRMM): results from LINKER-MM1. In: 11th World congress controversies in multiple myeloma (COMY) [poster]. 2025"},{"issue":"Suppl 2","key":"2207_CR20","doi-asserted-by":"publisher","first-page":"S90","DOI":"10.1016\/S2152-2650(24)01987-6","volume":"24","author":"A Suvannasankha","year":"2024","unstructured":"Suvannasankha A, Lee H, Bumma N, et al. Efficacy of linvoseltamab in prespecified high risk subgroups of patients with relapsed\/refractory multiple myeloma: results from LINKER-MM1. Clin Lymphoma Myeloma Leuk. 2024;24(Suppl 2):S90\u20131.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"Suppl 1","key":"2207_CR21","doi-asserted-by":"publisher","first-page":"3369","DOI":"10.1182\/blood-2024-199733","volume":"144","author":"MR Shah","year":"2024","unstructured":"Shah MR, Richter J, Lee HC, et al. Linvoseltamab in patients with relapsed\/refractory multiple myeloma: longer follow-up and selected high-risk subgroup analyses of the Linker-MM1 study. Blood. 2024;144(Suppl 1):3369.","journal-title":"Blood"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-025-02207-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-025-02207-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-025-02207-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T14:19:15Z","timestamp":1759241955000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-025-02207-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,29]]},"references-count":21,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["2207"],"URL":"https:\/\/doi.org\/10.1007\/s40265-025-02207-8","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,29]]},"assertion":[{"value":"22 June 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Arnold Lee is a contracted employee of Adis International Ltd\/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to this article and are responsible for its content.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval, consent to participate, consent to publish, availability of data and material, code availability"}}]}}